Succinylcholine is a depolarizing neuromuscular blocking agent used in acute medical and surgical settings to provide skeletal muscle relaxation. It is applied across domains where additional symptomatic support is needed.

Succinylcholine is used as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. This means it is commonly used to help with muscle relaxation required for procedures like inserting a breathing tube (tracheal intubation), ensuring reduced muscular activity during certain surgeries, and supporting mechanical ventilation.

It is often used during phases when symptoms become more noticeable, such as in emergency settings, and provides supportive relief when symptoms interfere with routine activities. It assists with maintaining functional stability by easing symptoms that create noticeable physiological strain. It is considered relevant in contexts involving heightened systemic burden. This medicine may assist with easing the overall symptom load during these supportive medical interventions.

---

Quick Fact: Relief for Symptoms of increased neurological or muscular activity

Regulatory References

1. PRESCRIBING INFORMATION PrQUELICIN® Succinylcholine Chloride Injection USP 20 mg / mL Sterile Solution Neuromuscular Blocking A

Official Eligibility for Succinylcholine Chloride

Succinylcholine Chloride is indicated for use in adults and pediatric patients as an adjunct to general anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation.

The medicine is absolutely contraindicated in several populations. It must not be used in patients with a personal or familial history of malignant hyperthermia or those with skeletal muscle myopathies. Use is also prohibited after the acute phase of severe injuries, including major burns and multiple trauma, due to the documented risk of life-threatening hyperkalemia. Contraindication also applies to known hypersensitivity to the drug.

Use is subject to regulatory restrictions in specific groups. In pediatric patients, use is generally reserved for emergency intubation only. Patients with renal impairment should not receive multiple or large doses. Those with severe liver disease or atypical plasma cholinesterase activity require caution as the drug's effect may be prolonged. For pregnant patients, the drug may be used, though physiological changes can prolong the effect; caution is advised during lactation.

Succicholine (also known as Succinylcholine) can interact with a wide range of other medications, potentially altering its effect or increasing the risk of adverse reactions. Because Succicholine is a neuromuscular blocking agent administered in controlled clinical settings, healthcare providers are responsible for managing these interactions.

Increased Neuromuscular Blockade

Co-administration with certain drugs can enhance the effects of Succicholine, leading to prolonged respiratory muscle paralysis or apnea. These include:

• Antibiotics: Specifically, aminoglycosides (e.g., gentamicin, amikacin) and polymyxins (e.g., colistin, polymyxin B).
• Local Anesthetics: Such as lidocaine and procainamide.
• Other Agents: Including quinidine, lithium, magnesium salts, and certain cholinesterase inhibitors (which inhibit the enzyme that metabolizes Succicholine).

Increased Risk of Malignant Hyperthermia

Succicholine carries a risk of triggering malignant hyperthermia (a rare but life-threatening reaction) when used concomitantly with volatile anesthetic agents, such as isoflurane or sevoflurane. This combination requires careful monitoring.

Risk of Hyperkalemia

Certain conditions or the use of other medications can predispose a patient to hyperkalemia (high potassium levels in the blood) when Succicholine is administered, including the use of some non-steroidal anti-inflammatory drugs (NSAIDs) and potassium-sparing diuretics. This is a critical consideration in patients with pre-existing conditions like major burns or trauma.

How Succicholine Works

The action of Suxamethonium Chloride (Succinylcholine Chloride) is entirely peripheral, focusing on the interface between the nerve and muscle fiber. The drug's effect is driven by two sequential mechanisms that ultimately lead to the temporary cessation of all voluntary muscle function.

Agonism and Sustained Activation of Nicotinic Receptors

The drug's primary mechanism is acting as an agonist (activator) of the nicotinic acetylcholine receptors (nAChR) on the motor end plate of skeletal muscle. Unlike the body's natural signaling molecule, Suxamethonium Chloride resists rapid breakdown, forcing a continuous opening of the ion channels. This persistent agonism rapidly transitions into the second mechanistic phase, resulting in initial, transient muscle twitching known as fasciculations.

Establishing the Depolarization Blockade

The continuous flow of ions due to persistent activation creates a state of sustained depolarization in the muscle membrane. This electrical state renders the muscle fiber refractory and unable to respond to further signals from the nerve—a mechanism known as a Phase I Depolarizing Block. This effectively halts the neuromuscular transmission pathway, leading directly to the physiological consequence: rapid onset flaccid paralysis of all skeletal musculature, including the diaphragm.

How to Use Succicholine

Succicholine (Suxamethonium Chloride) is administered only in controlled clinical settings under established protocols governing its route, dosage, and preparation. As an ultra-short-acting medication, its use is dictated by the immediate need for muscle relaxation during procedures such as tracheal intubation or surgical intervention.

---

Official Administration Protocol

Route and Administration Setting

The medicine is primarily delivered via Intravenous (IV) injection or continuous infusion. An Intramuscular (IM) injection is an alternative route utilized only when IV access is not feasible. Administration must occur under the immediate supervision of experienced clinicians in a setting equipped for artificial respiration and tracheal intubation. The drug is always administered after unconsciousness has been induced.

---

Standard Dosing and Schedule

Dosages are highly specific and weight-based, intended to achieve a rapid, short-lived effect. Dosing regimens follow established patterns:

• Adult IV Bolus: The usual dose is 0.6 mg/kg, with a range of 0.3 mg/kg to 1.1 mg/kg for brief procedures.
• Adult Continuous Infusion: When prolonged effect is necessary, the solution is administered at a rate typically ranging from 2.5 mg/minute to 4.3 mg/minute.
• IM Dosing: The dose for intramuscular use is 3 mg/kg to 4 mg/kg, with a maximum total dose that must not exceed 150 mg.

Preparation and Constraints: For infusion, the concentrated solution requires dilution to a final concentration of 1 mg/mL to 2 mg/mL in compatible solutions, such as isotonic saline. It is also explicitly stated that the solution must not be mixed with alkaline solutions, like barbiturates.

---

Population-Specific Use

Specific pediatric dosing is utilized: infants and small children typically receive 2 mg/kg IV, while older children receive 1 mg/kg IV. While general dosing in older adults is comparable to that in younger adults, multiple or large doses are restricted in patients with renal impairment, though a normal single dose may be administered.

Research Evidence / Overview of Studies for Succinylcholine

Evidence for Facilitating Endotracheal Intubation

Research has primarily focused on the use of Succinylcholine to facilitate endotracheal intubation, which is a medical procedure requiring the muscles to be completely relaxed quickly. Research has explored the use of Succinylcholine in situations requiring rapid muscle relaxation for intubation.

Researchers have conducted numerous randomized controlled trials (RCTs), often comparing Succinylcholine against a different type of muscle relaxant. These studies measure highly technical outcomes, such as the time to onset of muscle paralysis and the duration of effective relaxation. The studies included cohorts of adult patients studied in both routine surgical settings and urgent intubation scenarios.

Types of Studies and Measured Outcomes

Research examined immediate physiological changes by monitoring measured outcomes. Studies monitored measurements related to jaw and vocal cord relaxation. Other outcomes describing episodic or acute changes were tracked, such as measurements of heart rate and blood pressure recorded right after the drug's administration. The evidence contributes to the broader understanding of the time interval over which its effects are measured.

---

Evidence for Skeletal Muscle Relaxation During Surgery

Succinylcholine was also evaluated in research exploring its use for general skeletal muscle relaxation during surgery, especially when procedures are short and a quick return to spontaneous breathing is desired. The research in this area also involved comparative studies, examining the duration of muscle relaxation recorded for this drug against other available muscle relaxants.

Research examined the time it took for patients to recover full muscle function after the procedure, focusing on the spontaneous return of the ability to move and breathe without assistance. Findings describe patterns observed in the studies where the measured period of muscle relaxation was characterized as brief.

---

What the Research Still Does Not Fully Clarify

Although a large body of evidence exists related to the short-term use of Succinylcholine, some aspects still present uncertainty. Findings were mixed regarding the exact optimal dose required for intubation across all different patient body types and clinical states.

Data for certain groups remain insufficient. For individuals with rare genetic conditions affecting the enzymes that break down this drug, the primary evidence often comes from smaller collections of reports rather than large, organized trials. Evidence is limited in these specific populations, meaning the certainty remains low outside of the broad study groups.

Long-term effects are not fully established or actively studied beyond the perioperative period. Studies monitoring outcomes lasting weeks or months have not been reported in the available evidence.

Key Studies & References

1. Succinylcholine or rocuronium: a meta-analysis of the effects on intubation conditions - NCBI
2. Succinylcholine Chloride - StatPearls - NCBI Bookshelf (NIH)
3. Succinylcholine Pathway, Pharmacokinetics/Pharmacodynamics - ClinPGx

Common questions about Succicholine (FAQ)

---

Q: What is Succicholine used for?

Succicholine is a medication administered in clinical settings, primarily as a neuromuscular blocking agent to cause temporary muscle paralysis. It is used to facilitate endotracheal intubation (placing a breathing tube) and to relax skeletal muscles during certain procedures, such as surgery or mechanical ventilation, when quick onset and short duration of action are required.

---

Q: How quickly does Succicholine work?

This medication is known for its rapid onset of action. Following intravenous injection, effects are generally observed within 30 to 60 seconds. This speed is a key characteristic that makes it suitable for emergency procedures.

---

Q: How is Succicholine given?

Succicholine is only administered by healthcare professionals in controlled settings like hospitals. It is typically given as a fast intravenous (IV) injection or, less commonly, as an IV infusion. It is not a drug that patients administer to themselves.

---

Q: Can Succicholine cause muscle pain?

Some individuals may experience postoperative muscle pain following the use of Succicholine. This is thought to be related to the initial muscle activity the drug causes before full paralysis occurs. This muscle pain is usually temporary and may be managed by the healthcare team.

---

Q: What is the main safety warning associated with Succicholine?

A key safety warning involves the potential for malignant hyperthermia, a rare but serious reaction that affects skeletal muscle. Because of this risk, it is important that a patient's personal and family medical history is reviewed before administration.

---

Storage and Disposal of Succinylcholine Chloride Injection

Succinylcholine chloride injection must be stored strictly according to official labeling to maintain its stability and potency.

---

Storage Requirements

Official regulations require storage under refrigeration, maintaining a temperature between 2 C and 8 C (36 F and 46 F). It is mandated that the product must not be frozen and should be stored in the original container/package to protect from light.

---

Disposal and Handling

As a single-dose preparation, any unused portion of the solution must be discarded immediately. Disposal of residual medication and used syringes must be conducted according to institutional policy and local regulations. Used syringes must be placed in an appropriate sharps receptacle; do not recap needles after use. The medication must be stored out of the sight and reach of children.